semaglutide nash phase 3 essence Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults worldwide, yet many cases remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? Phase 3 ESSENCE trial: Semaglutide

This is a process where the liver breaks down substances before they can circulate through the rest of the body

For years, many of us have been moving earlier toward ablation because we see the benefit in practiceimproving symptoms and potentially preventing AF progression

A recombinant human glucagon-like peptide (GLP)-1albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis

Patients often find that their external transformation doesnt always match their internal self-perception

Abstract Obesity is a chronic, multifactorial disease in which accumulated excess body fat has a negative impact on health

Our practice has continued expanding its Peptide Therapy offerings over the past few years